Johnson&Johnson

Collaborative Working Project Executive Summary

Improving patient care, service delivery and capacity, through generating appropriate referrals from primary care to help with timely diagnosis and treatment of men with Prostate Cancer.

Project Title

A collaborative Working Agreement between The University Hospital Coventry and Warwickshire and Johnson and Johnson to improve patient care, service delivery and capacity, through generating appropriate referrals from primary care to help with timely diagnosis and treatment of men with Prostate Cancer.

Partner Organisations

The University Hospital Coventry and Warwickshire, Clifford Bridge Rd, Coventry CV2 2DX.

Johnson and Johnson, 50-100 Holmers Farm Way, High Wycombe HP12 4EG.

Project Rational

The NHS Long Term Plan makes a commitment for earlier diagnosis.

The National Faster Diagnosis Standard (FDS) ensures patients will be diagnosed or have cancer ruled out within 28 days of being referred urgently by their GP for suspected cancer.

For patients who are diagnosed with cancer, it means their treatment can begin as soon as possible.

A key metric in operational performance is the 62-day referral to treatment standard.

The Trust have identified that the challenge to meeting these targets is in early diagnosis which then impacts on referral to treatment and meeting these targets. The trust has been working with Prostate Cancer Research UK on a triage tool they believe may address these challenges and would like to pilot its use.

The objective is for the Company and the Trust to work collaboratively to map out, identify and recommend potential delivery solutions for the triage tool pilot.

Project Period

August 2025 - August 2026.

Project Objectives

Patient Specific:

Reduction in time for patients to access appropriate treatments. Reduction in delay for patients for follow-up and review of their treatment thereby having a potential to reduce complications associated with their treatment. Improved equity of access to treatment options as well as a

Johnson&Johnson

clearer pathway of care. Improvement in patient experience by ensuring a quicker more streamlined process to treatment decisions.

NHS Specific:

Reduce Cancer waiting times, including improving the Faster Diagnosis Standard and 62-day first treatment target and reducing backlogs. Increase Stage 1 & 2 Diagnosis to 75% by 2028. Remove inequalities and tackle the challenges of access to services, improving health outcomes and health inequalities

Johnson and Johnson company specific:

Greater understanding of the needs of the patients in Prostrate Cancer. Potential appropriate use of J&J medicines. Remove inequalities and tackle the challenges of access to services, improving health outcomes and health inequalities.

Contact Details

Johnson and Johnson company: Maria Walsh, Business Unit Director.

The University Hospital Coventry and Warwickshire, Mr Altan Omer Consultant Urologist.